Reference Population for Speckle Tracking Imaging (STE Normal)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01526252
Recruitment Status :
First Posted : February 3, 2012
Last Update Posted : April 24, 2017
Ottawa Heart Institute Research Corporation
Information provided by (Responsible Party):
Terrence Ruddy, Ottawa Heart Institute Research Corporation
The SCAR study uses a software program entitled QLAB, a proprietory program, developed by Philips Healthcare (Philips Healthcare, Andover, MA). Literature on two-dimensional speckle tracking imaging (2DSTE) is growing, but data relevant to the population in the SCAR study is minimal. Accumulation of data relevant for a population of subjects will provide a set of normal values for interpretation of 2DSTE and minimize any influences from differences in data produced from different companies. This data may also assist other researchers investigate other cardiac diseases and abnormalities.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Normal healthy males and females
Be between the ages of 20 - 80 years at study entry
Provide written informed consent and be able to comply with study procedures, including permission to access medical records
Have a BMI index equal to or less than 35
Less than 5% risk of developing coronary artery disease as determined using the Combined Diamond/Forrester and CASS data (ACC Stable CAD Guidelines)
Have taken cardioactive drugs within 6 months prior to examination
These include but are not limited to beta-blockers, calcium channel blockers, and angiotensin converting enzyme inhibitors
Currently clinically significant chronic or acute illness
Documented cardiovascular disease
Possess abnormal cardiac structure and function after examination with routine ECHO
This may include valvular defects, left ventricular hypertrophy, cardiomyopathies or pericardial disease